Discontinued — last reported Q1 '25
Business Segments · Equity in earnings, net
North American Pharmaceutical — Equity in earnings, net
McKesson North American Pharmaceutical — Equity in earnings, net remained flat by 0.0% to -$10.75M in Q1 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ1 2025
Rolls up toEquity Method Income
How to read this metric
Positive earnings contribute to overall segment profitability, while losses indicate underperformance of the underlying joint ventures or affiliates.
Detailed definition
The segment's proportionate share of the net income or loss from investments in unconsolidated affiliates or joint ventu...
Peer comparison
Commonly reported by large corporations that utilize joint ventures to expand into new markets or technologies.
Metric ID:
mck_segment_north_american_pharmaceutical_equity_in_earnings_netHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | -$43.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — equity in earnings, net?
- McKesson (MCK) reported north american pharmaceutical — equity in earnings, net of -$10.75M in Q1 2025.
- What does north american pharmaceutical — equity in earnings, net mean?
- The segment's share of profits or losses from its minority-owned business investments.